Connect with us

Technology

Cypherpunk Technologies Reports Second Quarter 2026 Financial Results

Published

2 hours ago

on

CAMBRIDGE, Mass., Aug. 12, 2026 /PRNewswire/ — Cypherpunk Technologies Inc., (Nasdaq: CYPH) (“Cypherpunk”), today reported financial results for the second quarter ended June 30, 2026.

“In the second quarter, Cypherpunk built upon the momentum established earlier this year through the disciplined execution of our Zcash digital asset treasury strategy, increasing our treasury holdings to 323,394.38 ZEC, and welcoming Dev Ojha, founder of Valar Group, as an Advisor,” said Douglas E. Onsi, President and CEO of Cypherpunk Technologies. “Our Leap Therapeutics subsidiary reached alignment with the FDA on a proposed Phase 3 trial in a DKK1-high, second-line, metastatic colorectal cancer population, with objective response rate as the primary endpoint to support accelerated approval and overall survival to support full approval in the United States and registration globally. We are conducting a strategic process to determine the best path to advance sirexatamab, whether as an independently financed spin-out company or with a partner who shares our commitment to cancer patients.”

“In an increasingly AI-driven economy, the demand for true privacy is moving from a technical preference to a civilizational necessity. Our execution in the second quarter reinforces Cypherpunk’s conviction in Zcash as a foundational monetary asset. By growing our ZEC treasury, expanding our world-class advisory team, and continuing to back core infrastructure developers like ZODL, we are systematically positioning Cypherpunk to capture the long-term value of digital privacy adoption,” said Will McEvoy, Chief Investment Officer of Cypherpunk.

Cypherpunk Highlights:

Zcash treasury holdings increased to 323,394.38 ZECAs of August 11, 2026, Cypherpunk held a total of 323,394.38 ZEC at an average purchase price of $341.83, representing approximately 1.92% of the total circulating supply of the Zcash network.ZEC is a digital currency that can be transmitted over a peer-to-peer payment system. Zcash uses a cryptographic method called “zero-knowledge proofs” to allow users to engage in financial transactions while maintaining greater privacy.Dev Ojha Appointed as an AdvisorCypherpunk appointed Dev Ojha, the founder of Valar Group, a leading development and research team focused on the Zcash Network, as an Advisor. Valar Group has taken a significant role in developing Zakura, a high-performance full node software designed for massive scalability of Zcash, and on the Ironwood shielded pool. Dev also serves as an official ZIP Editor for Zcash protocol standards. Cypherpunk’s Advisory Team also includes: Arjun Khemani, Zcash key opinion leader; Josh Swihart, CEO of ZODL; Jeff Tiller, Chief of Staff of Gemini; and Zooko Wilcox, Founder of Zcash and Chief Product Officer at Shielded Labs.

Leap Therapeutics Subsidiary Highlights:

Publication of randomized Phase 2 DeFianCe study in Clinical Cancer Research Leap Therapeutics announced the publication of results from the randomized Phase 2 DeFianCe (NCT05480306) study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in Clinical Cancer Research. The publication, “Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial,” reported the complete efficacy, safety, and biomarker analyses from the study and details the statistical basis for the DKK1 biomarker finding.The peer-reviewed analyses establish that, while the prespecified primary endpoint was not met in the intent-to-treat population, the benefit of sirexatamab increases as a patient’s baseline plasma DKK1 level rises — a relationship confirmed by independent statistical approaches and reinforced by the observation that high DKK1 predicts poorer outcomes on standard of care alone. Together, these findings define DKK1-high metastatic colorectal cancer (mCRC) as a biologically distinct population with high unmet need.Reached FDA alignment on registrational Phase 3 trial in DKK1-high colorectal cancer Leap Therapeutics held a Type C meeting with the FDA to discuss the DeFianCe results and proposed registrational path for sirexatamab in DKK1-high, second-line mCRC. Leap presented its proposed Phase 3 trial design, and the FDA provided feedback supporting key elements of that design, including the use of a DKK1 biomarker-selected patient population and a dual-endpoint structure intended to support both accelerated and full approval.Leap Therapeutics reached alignment with the FDA on a randomized, controlled Phase 3 trial evaluating sirexatamab in combination with investigator’s-choice fluoropyrimidine-based chemotherapy (FOLFIRI or mFOLFOX6) plus bevacizumab, compared with chemotherapy and bevacizumab alone. Approximately 270 patients with mCRC whose disease has progressed following one prior line of systemic therapy prospectively identified as DKK1-high using a baseline plasma DKK1 assay cut point are expected to be enrolled and randomized 1:1. Potential accelerated approval in the United States could be determined by objective response rate (ORR) in an initial group of approximately 160 patients, and overall survival (OS) will be evaluated in the full study population intended to support a filing for full approval in the United States and to support registration in markets outside the United States.A blood-based companion diagnostic would be developed in parallel to identify DKK1-high patients in routine clinical practice.Sirexatamab received Fast Track designation from FDAIn May 2026, the FDA granted Fast Track designation to sirexatamab in combination with fluoropyrimidine plus oxaliplatin- or irinotecan-based chemotherapy and bevacizumab, for the treatment of patients with DKK1-high mCRC whose disease has progressed following one prior systemic therapy.The Fast Track program is intended to facilitate the development and expedite the review of drug candidates and vaccines that treat serious conditions and fill an unmet medical need. Programs with Fast Track designation may benefit from frequent communication with the FDA, in addition to a rolling submission of the marketing application.Business updateLeap Therapeutics has initiated a strategic process to identify the best path forward for sirexatamab and to secure the resources required to advance the program into Phase 3 development. The process is expected to consider a range of alternatives, which may include financing the program as an independent entity, or a strategic transaction with a pharmaceutical or biotechnology company, including a partnership, license, collaboration, sale, or other business combination.There can be no assurance that the strategic process will result in any transaction or financing, or that any transaction or financing that is completed will be on terms favorable to the Company or its stockholders. The Company has not set a timetable for the conclusion of the process and does not intend to disclose developments unless and until it determines that further disclosure is appropriate or required.

Selected Second Quarter 2026 Financial Results

Net income was $39.4 million, or $0.18 per diluted share, for the second quarter of 2026, compared to a net loss of $16.6 million for the second quarter of 2025. The change was primarily due to a $46.0 million unrealized gain on the fair value of the Company’s ZEC treasury holdings during the second quarter of 2026, which are marked to market at the end of each period. During the second quarter of 2026, the price of ZEC increased from $243.35 to $400.09.

Research and development expenses were $0.2 million for the three months ended June 30, 2026, compared to $10.5 million for the same period in 2025. The decrease was primarily due to a decrease in clinical trial and manufacturing expenses due to the completion of the clinical trials, together with a decrease in payroll and related expenses associated with the 2025 reduction in force.

General and administrative expenses were $4.5 million for the three months ended June 30, 2026, compared to $1.8 million for the same period in 2025. The increase of $2.7 million for the three months ended June 30, 2026 was primarily due to a $1.7 million increase in stock-based compensation related to restricted stock units granted to general and administrative employees and directors in the fourth quarter of 2025, a $0.8 million increase in payroll and related expenses, and a $0.2 million increase in professional fees.

During the three months ended June 30, 2026, the Company recorded a $46.0 million unrealized gain on the change in fair value of the Company’s ZEC treasury holdings as the price of ZEC increased during the second quarter of 2026 from $243.35 to $400.09.

Cash and cash equivalents totaled $7.6 million on June 30, 2026, and ZEC treasury holdings, categorized as digital asset receivable, totaled $129.4 million based on the ZEC price of $400.09 on June 30, 2026.

About Cypherpunk

Cypherpunk Technologies is a privacy technology company. The Company’s mission is to advance technologies that guarantee privacy for humans on the internet. Cypherpunk pursues this mission through two primary strategies: accumulating Zcash (ZEC); and investing in, acquiring, and building technologies that push the frontier of privacy forward. Additionally, through its subsidiary Leap Therapeutics, the Company is developing novel therapies for patients with cancer, continuing the development of sirexatamab and FL-501. For more information about the Company, visit our websites at http://www.cypherpunk.com and http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov.

FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning. Forward-looking statements address various matters including statements relating to the value of the Company’s ZEC holdings, the investment in Zcash Open Development Labs (“ZODL”), or digital assets held or to be held by the Company, the expected future market, price, and liquidity of ZEC or other digital assets the Company acquires, the macro and political conditions surrounding Zcash or digital assets, the Company’s plan for value creation and strategic advantages, market size and growth opportunities, regulatory conditions, competitive position and the interest of other corporations in similar business strategies, technological and market trends, and future financial condition and performance. Risks and uncertainties of the digital asset treasury strategy include, among others: (a) risks relating to the Company’s operations and business, including the highly volatile nature of the price of ZEC; (b) the risk that material changes in the price of ZEC, such as decreases in price, will result in significant changes to the Company’s financial statements, such as unrealized losses on fair value of ZEC holdings and net loss; (c) the risk that the price of the Company’s common stock may be highly correlated to the price of ZEC; (d) the risk that the Company will fail to realize the anticipated benefits of the ZEC digital asset treasury strategy or the investment in ZODL; (e) risks related to the custody of our ZEC and our reliance on Gemini Space Station and its affiliates for trading and custody services; (f) changes in business, market, financial, political and regulatory conditions; (g) risks related to increased competition in the industries in which the Company does and will operate; (h) risks relating to significant legal, commercial, regulatory and technical uncertainty regarding digital assets generally; (i) risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and (j) the Company’s ability to comply with the continued listing requirements of the Nasdaq Capital Market.

With respect to our biotechnology operations, important factors that could cause actual results to differ materially from our plans, estimates or expectations could include, but are not limited to: (i) the DeFianCe study did not meet its prespecified primary endpoint of progression-free survival in the intent-to-treat population; (ii) the DKK1 biomarker subgroup and interaction analyses were exploratory, were based on a limited number of patients, were not adjusted for multiplicity, and may not be replicated in a prospective clinical trial; (iii) the impact of imbalances between treatment arms in the DKK1 subgroups; (iv) the risk that alignment with the FDA on trial design does not constitute agreement that any trial will succeed or that any marketing application will be accepted or approved, and the FDA may change its position at any time; (v) accelerated approval, if pursued, requires that the surrogate endpoint be reasonably likely to predict clinical benefit and is subject to confirmatory trial requirements and possible withdrawal if such requirements are not satisfied; (vi) the Company’s ability to initiate or complete the Phase 3 trial on the anticipated timeline or at all; (vii) the Company’s ability to obtain additional capital to advance sirexatamab on acceptable terms or at all; (viii) that risk that the strategic process may not result in any transaction or financing, may be terminated at any time, and any resulting transaction may not be on terms favorable to the Company or its stockholders; (ix) the Company’s ability to develop and validate a companion diagnostic; (x) the success of competing therapies; (xi) the Company’s ability to secure manufacturing capacity for sirexatamab; and (xii) the Company’s ability to maintain and protect its intellectual property rights.

New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. The Company may not actually achieve the forecasts disclosed in such forward-looking statements, and you should not place undue reliance on such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the SEC, or as may be included in other reports or information we file with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in its subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither the Company, nor any of its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

Cypherpunk Technologies Inc.

Consolidated Balance Sheets

(in thousands, except share and per share amounts)

June 30, 

December 31, 

2026

2025

(Unaudited)

Assets

Current assets:

Cash and cash equivalents

$           7,624

$         14,035

Digital assets receivable

1,29,387

1,47,404

Research and development incentive receivable

–

602

Prepaid expenses and other current assets

539

40

Total current assets

1,37,550

1,62,081

Right of use assets, net

38

38

Deferred costs

348

401

Deposits

33

662

Other investment

5,000

–

Total assets

$       1,42,969

$       1,63,182

Liabilities and Stockholders’ Equity 

Current liabilities:

Accounts payable

$              588

$           1,981

Accrued expenses

1,014

2,067

Income tax payable

97

472

Lease liability 

38

38

Total current liabilities

1,737

4,558

Non-current liabilities:

Deferred tax liability

1,913

5,118

Total liabilities

3,650

9,676

Stockholders’ equity:

Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 shares issued
    and outstanding as of June 30, 2026 and December 31, 2025, respectively

–

–

Common stock, $0.001 par value; 490,000,000 shares authorized; 107,764,382 and 83,851,051
  shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively

108

84

Stock subscription receivable

–

(150)

Additional paid-in capital

6,39,618

6,16,216

Accumulated other comprehensive loss

(81)

(95)

Accumulated deficit 

(5,00,326)

(4,62,549)

Total stockholders’ equity 

1,39,319

1,53,506

Total liabilities and stockholders’ equity 

$       1,42,969

$       1,63,182

 

Cypherpunk Technologies Inc.
Consolidated Statements of Operations
(in thousands, except share and per share amounts)

 

(Unaudited)

(Unaudited)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

Operating expenses:

Research and development

$                  197

$             10,537

$                  358

$             23,448

General and administrative 

4,492

1,817

9,148

4,823

Restructuring charges

–

4,527

–

4,527

    Total operating expenses

4,689

16,881

9,506

32,798

Loss from operations

(4,689)

(16,881)

(9,506)

(32,798)

Interest income 

63

246

158

683

Interest expense

(6)

(7)

(13)

(13)

Australian research and development incentives

–

1

–

56

Change in fair value of embedded derivative

45,993

–

(31,562)

–

Foreign currency gain (loss)

1

(2)

1

(6)

Income (loss) before income taxes

41,362

(16,643)

(40,922)

(32,078)

Benefit from (provision for) income taxes

(1,973)

–

3,145

–

Net income (loss) attributable to common stockholders

$             39,389

$            (16,643)

$            (37,777)

$            (32,078)

Net income (loss) per share 

Basic 

$                 0.21

$               (0.40)

$               (0.21)

$               (0.78)

Diluted

$                 0.18

$               (0.40)

$               (0.21)

$               (0.78)

Weighted average common shares outstanding 

Basic

18,43,28,441

4,14,44,979

17,62,60,808

4,13,57,423

Diluted

21,73,43,013

4,14,44,979

17,62,60,808

4,13,57,423

 

 Leap Therapeutics, Inc. 
 Condensed Consolidated Statements of Cash Flows 
 (in thousands) 

 

 (Unaudited) 

 (Unaudited) 

 Three Months Ended June 30, 

 Six Months Ended June 30, 

2026

2025

2026

2025

 Cash used in operating activities 

$          (2,692)

$        (14,486)

$          (6,122)

$        (28,966)

 Cash used in investing activities 

(9,544)

–

(18,544)

–

 Cash provided by (used in) financing activities 

13,167

(119)

18,242

(180)

 Effect of exchange rate changes on cash and cash equivalents 

4

22

13

27

 Net increase (decrease) in cash and cash equivalents 

935

(14,583)

(6,411)

(29,119)

 Cash and cash equivalents at beginning of period 

6,689

32,713

14,035

47,249

 Cash and cash equivalents at end of period 

$           7,624

$          18,130

$           7,624

$          18,130

CONTACT:
Douglas E. Onsi
President & Chief Executive Officer
Cypherpunk Technologies Inc.
617-714-0360

For Investors:
Matthew DeYoung
Investor Relations
Argot Partners
212-600-1902
leap@argotpartners.com

For Media:
Jacqueline Ortiz Ramsay
It Factor Strategies
954-294-3249
jacqueline@itfactorstrategies.com

 

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/cypherpunk-technologies-reports-second-quarter-2026-financial-results-302849085.html

SOURCE Cypherpunk Technologies Inc.

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

PVFARM Commercially Launches Energy Storage Design Platform RE STACK

Published

7 minutes ago

on

August 12, 2026

By

Integration into the PVFARM workflow streamlines renewable energy project design while unlocking new energy storage market opportunities

NEWPORT BEACH, Calif., Aug. 12, 2026 /PRNewswire/ — Today, PVFARM launched the commercial version of its platform for utility-scale battery energy storage (BESS) layout exploration, RE STACK. Together with PVFARM, RE STACK forms an expanding suite of tools for utility-scale renewable energy design that enable teams to explore a wide range of layout options before progressing into detailed engineering.

RE STACK enables engineers to configure utility-scale BESS projects from manufacturer specifications and rapidly explore site layouts, road concepts, and medium-voltage collection topologies before detailed engineering begins.

Key features include

Battery recommendationEquipment configurationBESS layout generationRoad strategy planningMedium-voltage collection topology planning

Collaboration with over 80 companies during RE STACK and RE PILOT’s beta testing directly shaped the platforms’ capabilities. Throughout the beta testing process, participants provided feedback on critical design considerations, ranging from equipment selection to power conversion system (PCS) architecture, augmentation planning, fire safety access, and site topology. Beyond ensuring that the platforms solve real-world project challenges, this extensive collaboration also provided the insight needed to shape RE STACK and RE PILOT so they could deliver intuitive, informed decision-making while reflecting the latest technology and market dynamics.

“A lot of software takes forever to make even small changes, but RE STACK stands out from the competition. At Sun2O, we’ve received a lot of value and saved a lot of time from the platform. RE STACK is a highly useful tool for evaluating our sites, understanding the challenges we face, and being able to leverage PVFARM’s existing grading capabilities alongside it,” said Vatan Kumar, Vice President, Development Engineering at Sun2O. “Overall, PVFARM’s drive to capture all the detailed project inputs and challenge the norm is what impresses me most about RE STACK.”

“The future of engineering isn’t just designing faster. It’s exploring more before you design,” said Maksim Markevich, Chief Technology Officer of PVFARM. “With RE STACK and RE PILOT, we’re giving engineering teams the ability to evaluate far more possibilities before committing to detailed engineering. The result is better-informed decisions, greater confidence, and a workflow that keeps pace with the growing complexity of utility-scale renewable energy projects.”

The International Energy Agency has called energy storage the “fastest-growing power technology today,” and the response to RE STACK’s beta test program underscores that: 45 organizations enrolled in under a month. Yet, BESS projects often need repeated manual layout concepts before a workable site plan emerges. Stuck between increasing design work and widening applications, developer and EPC teams can rely on RE STACK to generate, evaluate, and compare alternatives earlier by generating BESS layouts automatically, exploring thousands of layout alternatives, testing different road configurations, and MV collection strategies.

About RE STACK

RE STACK enables battery developers and EPCs to start evaluating BESS layouts without the manual concept grind. Users can generate layouts and compare alternatives while the design is still flexible. This helps teams understand how much equipment can fit, how layouts perform under different assumptions, how roads affect site utilization, and how MV collection choices influence the arrangement.

Unlike traditional design methods that make equipment determinations from desired storage capacity, RE STACK answers key questions in the layout stage of BESS design. Learn more at restack.pvfarm.io.

About PVFARM

Launched by a team of builders, PhDs, engineers, and software experts, PVFARM is building the decision intelligence layer for utility-scale solar. The platform brings layout, electrical, structural, civil and financial workflows into one connected design system, helping project teams align around the same numbers, constraints, and tradeoffs early enough to shape outcomes earlier. With more than half of top U.S. utility-scale EPCs using PVFARM as part of their core workflow, PVFARM is helping drive the solar industry make better decisions – from first layout through long-term performance.

Learn more at pvfarm.io or www.linkedin.com/company/pv-farm.

Media Contact
PVFARM
media@pvfarm.io
1-949-804-9647

FAQ

Who uses RE STACK?RE STACK is designed for utility-scale renewable energy developers, engineering firms, independent power producers (IPPs), and engineering, procurement, and construction (EPC) contractors responsible for planning, designing, and optimizing solar + storage and battery energy storage projects.How does RE STACK improve battery energy storage system (BESS) design?RE STACK replaces manual concept development with automated layout generation and comparison. Users can configure manufacturer-specific battery containers, PCS equipment, transformers, spacing requirements, roads, and medium-voltage collection strategies to rapidly evaluate how different design choices affect land utilization and project configuration before committing engineering-intensive resources.How is RE STACK different from traditional BESS design software?Traditional workflows often rely on manually creating a small number of layout concepts after major equipment decisions have already been made. RE STACK allows engineers to explore numerous feasible layouts earlier in project development, helping teams understand the design implications of equipment selection, site constraints, road placement, and electrical topology before detailed engineering begins.Can RE STACK work with different battery manufacturers and equipment vendors?Yes, RE STACK allows users to configure layouts using manufacturer-specific battery containers, power conversion systems (PCS), transformers, equipment dimensions, and spacing requirements. This allows engineering teams to compare different equipment configurations and evaluate their impact on project layouts.Can RE STACK export layouts for engineering workflows?Yes, RE STACK supports importing project boundaries using KMZ and DXF files and can export layouts to DXF for continued engineering work as well as PDF summaries for project review and collaboration.Why are early-stage layout decisions important for utility-scale solar and battery storage projects?Early layout decisions influence land utilization, constructability, equipment quantities, electrical design, project economics, and long-term performance. Evaluating more layout alternatives before detailed engineering helps teams identify better-performing projects while reducing redesign work later in development.

View original content to download multimedia:https://www.prnewswire.com/news-releases/pvfarm-commercially-launches-energy-storage-design-platform-re-stack-302849141.html

SOURCE PVFARM

Continue Reading

Technology

Advance America Introduces Program to Reward Word-of-Mouth Referrals

Published

7 minutes ago

on

August 12, 2026

By

The new Refer It Forward program pays participants $50 for every successful referral

GREENVILLE, S.C., Aug. 12, 2026 /PRNewswire/ — Advance America, a leading provider of consumer financial services, has launched its new Refer It Forward program. For every referred friend who becomes a new Advance America customer, the referrer earns $50. No guessing; just one flat reward.

The program kicked off in May and arrives at a moment when many U.S. households are navigating rising costs and stagnant wages. With that kind of financial pressure, people are looking for practical ways to support the friends and family they care about. Refer It Forward makes that possible while rewarding them for it.

“Word of mouth has always been one of our most powerful connections to the communities we serve,” said Laura McCutcheon, Vice President of Marketing at Advance America. “Refer It Forward is our way of recognizing that and giving back to the people who help spread the word.”

How it works

Participating is simple:

Refer a friend using a personalized referral linkEarn $50 when that friend becomes a new Advance America customer and their loan is fundedChoose your reward: a Visa prepaid card or a retail gift card

A practical way to help and earn

For many Advance America customers, the referral program isn’t just about earning — it’s about being there for someone who needs a hand. Whether it’s a friend facing an unexpected expense or a family member who needs fast access to funds, a simple referral can make a real difference. With a flat $50 reward, customers always know exactly what they’ll earn.

“We wanted to create something that felt real and achievable — not a program with so many conditions that it loses its appeal,” added McCutcheon. “Fifty dollars for helping a friend is something we can all get behind.”

About Advance America

Advance America is a licensed and regulated lender providing convenient loan options online and in store at 700+ locations across 23 states.  

Since 1997, we’ve helped millions of families navigate life’s financial moments. We believe borrowing money should be simple, fast, and free from judgment — with clear terms and real human support when it matters most.

Making it work looks different for everyone. For us, it means backing you up with simple, honest money solutions that keep you moving forward.

Media Contact: mediarequest@teampurpose.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/advance-america-introduces-program-to-reward-word-of-mouth-referrals-302845280.html

SOURCE Advance America

Continue Reading

Technology

Strativera Now Credentialed Across Both Major CRM Ecosystems as Salesforce Listing Goes Live

Published

7 minutes ago

on

August 12, 2026

By

The Cherry Hill agency pairs a new Salesforce AppExchange consulting listing with HubSpot Solutions Partner status and Google Partner standing, each independently verifiable.

CHERRY HILL, N.J., Aug. 12, 2026 /PRNewswire/ — Strativera, a digital marketing and revenue operations agency serving mid-market and private-equity-backed companies, today announced its Salesforce consulting practice is live on Salesforce AppExchange, giving the firm credentialed standing across both dominant CRM ecosystems.

The listing, Strativera Revenue Operations and Salesforce Consulting, appears in AppExchange’s Salesforce Consultants directory and covers org audits and cleanup, Sales Cloud implementation, lead lifecycle design, CRM migrations, and executive dashboards connecting campaigns to closed revenue. It joins the firm’s HubSpot Solutions Partner listing, which carries its own public 5.0 rating, and its standing in Google’s Partners directory.

“Most agencies pick a CRM camp because credentialing across ecosystems is expensive and slow,” said Janae Tanner, Co-Founder and Vice President of Growth and Client Success at Strativera. “We did it deliberately. A client’s CRM decision should follow their sales process, not whichever logo their agency happens to carry. Now we can give an honest answer in either direction, and every credential behind that answer sits in the issuer’s own directory rather than on our website.”

All three are publicly verifiable. The Google Partners listing is at https://appexchange.salesforce.com/appxListingDetail?listingId=2767129d-ff82-4774-871e-136a99f7ca04, and the HubSpot Solutions Partner listing at ecosystem.hubspot.com/marketplace/solutions/strativera.

The firm’s client ratings stand at 5.0 across Google, Clutch and GoodFirms, spanning 24 Clutch reviews and 8 GoodFirms reviews. Strativera has also joined the Clutch Guarantee, backing new engagements originating through Clutch with a 14-day, no-questions-asked money-back commitment.

“Buyers should be able to check everything an agency says about itself, and with us they can,” Tanner said. “The credentials live in the issuers’ directories. The reviews live on platforms we do not control. And new Clutch engagements now carry a 14-day guarantee. Verification is the standard our clients’ buyers hold them to, so it is the standard we hold ourselves to.”

Founded in June 2025, Strativera has grown to four offices, with headquarters in Cherry Hill Township, New Jersey, and locations in Manahawkin, New Jersey, Tampa, Florida, and Las Vegas, Nevada. The firm reports more than $104 million in client-attributed revenue growth and an average 28 percent reduction in customer acquisition cost across engagements spanning more than 17 industries.

About Strativera

Strativera is a digital marketing and revenue operations agency located at 7 Cooper Landing Rd, Cherry Hill Township, NJ 08002. Built for growth-stage, mid-market and private-equity-backed companies, Strativera connects strategy, campaigns, CRM and reporting into one revenue system delivered by senior operators rather than junior teams. Learn more at strativera.com.

Media Contact
Janae Tanner, Co-Founder and VP of Growth and Client Success
Strativera
(856) 380-0416
420580@email4pr.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/strativera-now-credentialed-across-both-major-crm-ecosystems-as-salesforce-listing-goes-live-302849155.html

SOURCE Strativera

Continue Reading

Trending